- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe-09-01-2010
Pharmaceutical Technology Europe
Approach social media with caution?
September 01, 2010
22
9
No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.
A SWOT Analysis Of The Biosimilars Market
September 01, 2010
Manufacturing
22
9
A Strengths, Weaknesses, Opportunities and Threats analysis of the biosimilars market is given.
Behind The Scenes Of Pharma Mergers And Acquisitions
September 01, 2010
Industry Insider
22
9
Despite the poor economic climate, large-scale mergers and acquisitions in the pharmaceutical industry struck back with a vengeance in 2009.
How A CMO Can Compete In An Increasingly Competitive Market
September 01, 2010
Special Feature
22
9
In an increasingly competitive landscape, outsourcing providers are under mounting pressure to get their name out there and secure new and repeat business.
The Effect Of The Financial Crisis On Outsourcing
September 01, 2010
Special Feature
22
9
The economic crisis has affected outsourcing providers in several ways.
Outsourcing: The Indian Perspective
September 01, 2010
Special Feature
22
9
India has evolved from a low-cost region to an area with extensive technical capability and high quality standards.
Biosimilars: Perception, cost And The Impact On Biotech Innovation
September 01, 2010
Manufacturing
22
9
In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.
Handling HPAPIs
September 01, 2010
Interview
22
9
The manufacture of high potency active pharmaceutical ingredients (HPAPIs) is on the rise with R&D projects showing a continuing interest in these products.
Continuous Processing: Is The Pharma Industry Finally Coming Round To The Idea?
September 01, 2010
Manufacturing
22
9
Industry experts discuss the merits of continuous processing technology and explain why pharma manufacturers should realize the benefits these technologies offer.
Use Of RFID Asset Management Systems For Monitoring Analytical Instrumentation
September 01, 2010
Analytics
22
9
Utilizing integrated active radio frequency identification (RFID) and real-time asset management systems can yield commercial and compliance benefits.
How Responsible Should The Sponsor Be For The Outsourcing Provider's Success?
September 01, 2010
Special Feature
22
9
When assessing the competencies of an outsourcing service provider, sponsor companies must pay a great deal of attention to the cGMP compliance level of the provider.
Launching And Commercializing Biosimilars
September 01, 2010
Manufacturing
22
9
Many hurdles lie between a biosimilar and success on the market. In particular, there are three main questions that companies will be asking themselves.
Implementing A Successful Lean Program: Where Do You Begin?
September 01, 2010
22
9
A case study describing how Lean can drive the creation of an improved culture within pharmaceutical companies.
Clinical And Cost Considerations Of Developing A Biosimilar
September 01, 2010
Manufacturing
22
9
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
How To Identify The Right Outsourcing Partner In Asia–Pacific
September 01, 2010
Special Feature
22
9
How to find the right partner in Asia–Pacific is a very complex question and there is no uniform answer.
Understanding The Requirements For Effective Nasal Drug Delivery
September 01, 2010
Drug Delivery
22
9
One particularly crucial parameter for nasal sprays is the size of the droplets produced during actuation, which can potentially impact bioavailability.
The Biosimilars Market Today And Tomorrow
September 01, 2010
Manufacturing
22
9
Last year, the global market for biological products exceeded $125 billion, accounting for 17% of the total market for pharma/biopharma products.